Basic Study
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Mar 26, 2020; 12(3): 222-240
Published online Mar 26, 2020. doi: 10.4252/wjsc.v12.i3.222
CR6-interacting factor-1 contributes to osteoclastogenesis by inducing receptor activator of nuclear factor κB ligand after radiation
Li-Xin Xiang, Qian Ran, Li Chen, Yang Xiang, Feng-Jie Li, Xiao-Mei Zhang, Yan-Ni Xiao, Ling-Yun Zou, Jiang F Zhong, Shengwen Calvin Li, Zhong-Jun Li
Li-Xin Xiang, Qian Ran, Li Chen, Yang Xiang, Feng-Jie Li, Xiao-Mei Zhang, Yan-Ni Xiao, Zhong-Jun Li, Laboratory Medicine Center, Department of Blood Transfusion, Lab of Radiation Biology, The Second Affiliated Hospital, Third Military Medical University, Chongqing, 400037, China
Qian Ran, Yang Xiang, Jiang F Zhong, Department of Otolaryngology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, United States
Ling-Yun Zou, Bioinformatics Center, College of Basic Medical Sciences, Third Military Medical University, Chongqing 400038, China
Shengwen Calvin Li, CHOC Children’s Research Institute, Children’s Hospital of Orange County, University of California, Irvine, CA 92868, United States
Author contributions: Li ZJ and Xiang LX conceived the study; Xiang LX designed and performed most experiments and data analysis; Chen L, Xiang Y, Li FJ, Zhang XM, Xiao YN, Zou LY, Zhong JF, Li SC, and Ran Q assisted with experiments and data analysis; Xiang LX wrote and edited the manuscript; Li ZJ supervised the study; all authors read and approved the final manuscript.
Supported by National Natural Science Foundation of China, No. 81502754 and No. 31571352; and Interdisciplinary and International Cooperation Projects of The Second Affiliated Hospital, Third Military Medical University, No. 2016YXKJC0.
Institutional review board statement: Not applicable.
Institutional animal care and use committee statement: All animal studies performed were approved by the Laboratory Animal Welfare and Ethics Committee Of the Third Military Medical University.
Conflict-of-interest statement: The authors report no conflicts of interest in this work.
Data sharing statement: No additional data are available.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Zhong-Jun Li, MD, Professor, Chief, Laboratory Medicine Center, Department of Blood Transfusion, Lab of Radiation Biology, The Second Affiliated Hospital, Third Military Medical University, Xinqiao Road, Chongqing 400037, China. johnneyusc@gmail.com
Received: January 23, 2020
Peer-review started: January 23, 2020
First decision: February 19, 2020
Revised: March 9, 2020
Accepted: March 15, 2020
Article in press: March 15, 2020
Published online: March 26, 2020
Processing time: 62 Days and 21.2 Hours
Core Tip

Core tip: Current treatment of osteoporosis is based mainly on inhibiting bone resorption or stimulating bone generation to increase bone mass; however, the side-effects of some drugs affect long-term administration and adherence. There is still a lack of effective preventive or therapeutic method for radiation-induced bone injury. Because of the contribution of adipocytes to osteoporosis, future drug screening should target not only the regulation of the balance between bone formation and bone resorption but also the balance between osteogenic and adipogenic differentiation. Here, through screening, we identified five CR6-interacting factor-1 inhibitors targeting CR6-interacting factor-1-protein kinase cyclic adenosine monophosphate-activited catalytic subunit alpha interaction interface that could dramatically reduce receptor activator of nuclear factor κB ligand secretion and adipogenesis. Our study provides insights into potential therapeutic strategies for radiation-induced bone injury.